Quick Answer
Anika Therapeutics, Inc. reported Revenue (ASC 606) of $112.82 million for fiscal year 2025.
Anika Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $112.82M | -5.9% |
| 2024 | $119.91M | -0.7% |
| 2023 | $120.79M | +6.1% |
| 2022 | $113.83M | -23.0% |
| 2021 | $147.79M | +13.3% |
| 2020 | $130.46M | +13.8% |
| 2019 | $114.61M | +8.6% |
| 2018 | $105.56M | -6.9% |
| 2017 | $113.42M | +9.7% |
| 2016 | $103.38M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $27.82M | -5.9% | -1.4% |
| June 30, 2025 | $28.22M | -8.2% | +7.8% |
| March 31, 2025 | $26.17M | -9.8% | -11.5% |
| September 30, 2024 | $29.56M | -28.7% | -3.8% |
| June 30, 2024 | $30.72M | -30.6% | +5.9% |
| March 31, 2024 | $29.02M | -23.5% | -30.0% |
| September 30, 2023 | $41.47M | +3.0% | -6.4% |
| June 30, 2023 | $44.30M | +11.7% | +16.8% |
- Anika Therapeutics, Inc. showed a decrease of -5.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, Anika Therapeutics, Inc.’s revenue (asc 606) has grown by 9.1% (from $103.38 million to $112.82 million).
- The most recent figure is from Anika Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: